111P - Real-world treatment patterns and clinical outcomes in Chinese stage III non-small cell lung cancer (NSCLC) patients: Results of MOOREA study

Background

About one-third of newly diagnosed NSCLC was stage III unresectable and resectable patients (pts). Stage III NSCLC have high heterogeneity. Currently, real-world molecular testing pattern, treatment pattern and the associated survival outcomes are limited.

Methods

This prospective real-world study enrolled untreated stage III NSCLC pts from 28 hospitals in China. Unresectable and resectable pts were studied separately in cohort 1(C1) and cohort 2(C2). The primary endpoint was treatment pattern of C1, secondary endpoints included molecular testing pattern, progression-free survival (PFS), overall survival (OS) of C1 and treatment pattern of C2.

Results

From 2019 July to 2022 February, 486 pts were included, with 379 pts in C1 and 107 pts in C2. Median age was 63 years (range: 25-85), 82.9% were male. The testing/positive rates of EGFR, ALK, and PD-L1 (≥1%) were 20.0%/39.2%, 15.0%/23.3%, and 13.0%/73.0%, respectively. In C1, 201 (53.0%) pts received radiotherapy (RT), among whom 86.1% (173/201) were chemoradiotherapy (CRT), including 63.6% (110/173) concurrent CRT (cCRT) and 36.4% (63/173) sequential CRT (sCRT). Following CRT, 53.8% pts received consolidation therapy, among whom 58.1 % were immunotherapy-based (IO-based) therapy, of with 35.2% were durvalumab-based therapy. For pts without RT, chemotherapy only or chemotherapy plus anti-angiogenesis therapy, was most commonly used (60.1% [107/178]), followed by chemoimmunotherapy (27.0% [48/178]). In C2, 61.9% had neo-adjuvant treatment, with chemotherapy alone (40.0%) or combined with IO (40%) as the main regimens. Adjuvant treatment was planned for 71.4% pts. As of April 30, 2024 (data cut-off), for pts in C1, the overall median PFS (mPFS) and median OS (mOS) were 12.6 months (95% CI, 11.0-14.0) and 33.3 months (95% CI, 29.6-NE), respectively. For pts in C1 treated with CRT followed by IO-based consolidation therapy, mPFS and mOS were 15.1 months (95% CI, 12.7-28.5) and NE (95% CI, 30.5-NE), respectively. The 2-yr OS rate was 82.6% (95%CI, 69.2-90.6).

Conclusions

MOOREA study presents real-world testing and treatment patterns in stage III NSCLC and showed the effectiveness of CRT followed by IO-base consolidation therapy in this setting.

Clinical trial identification

NCT04023812.

Legal entity responsible for the study

AstraZeneca.

Funding

AstraZeneca.

Disclosure

All authors have declared no conflicts of interest.